Drug cocktail aims to stall pancreatic cancer in patients who have run out of options
NCT ID NCT00640978
First seen Jul 07, 2026 · Last updated Jul 08, 2026 · Updated 1 time
Summary
This phase 2 trial tests whether combining two drugs—erlotinib and everolimus—can slow the growth of advanced pancreatic cancer in patients who have already received at least one prior treatment. The study enrolls people with unresectable or metastatic pancreatic adenocarcinoma and measures how many survive at 6 months, as well as how long the cancer stays under control. Researchers are also monitoring safety and side effects of the combination.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- erlotinib and everolimus
- What this could lead to
- If successful, this drug combination could offer a new treatment option to slow advanced pancreatic cancer in patients who have already tried other therapies.
- What could go wrong
- This is an early-phase trial with only 16 participants, so results may not apply broadly. The combination may cause side effects and might not improve survival.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED PANCREATIC ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
U.T.M.D. Anderson Cancer Center
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can High-Dose vitamin c boost Chemo's punch against pancreatic cancer?
- Can a cancer pill keep working outside the lab? a Real-World test begins
- Ancient acupressure meets modern medicine: can ear stimulation replace standard Anti-Nausea drugs?
- AI trained on thousands of pancreatic cancer cases could revolutionize diagnosis
- New oral drug targets Cancer's growth engine in advanced tumours
- New imaging compound targets Hard-to-Spot cancers